TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thiogenesis Therapeutics Corp ( (TSE:TTI) ) has issued an announcement.
Thiogenesis Therapeutics Corp announced that its common shares are now trading on the OTCQX Best Market in the U.S., under the ticker symbol TTIPF, which will enhance the company’s visibility and accessibility to U.S. investors. Additionally, the company has received regulatory clearance to initiate a Phase 2 clinical trial in Europe for treating MELAS, a rare mitochondrial disorder. The trial is anticipated to start after completing necessary administrative procedures. This development marks a significant step forward in Thiogenesis’ efforts to advance treatments for rare pediatric diseases, potentially boosting its industry positioning and impact on stakeholders.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics Corp is a clinical-stage biopharmaceutical company based in San Diego, CA, focused on developing sulfur-containing prodrugs. These prodrugs act as precursors to previously approved thiol compounds and have the potential to treat serious pediatric diseases with unmet medical needs. The company’s target indications include mitochondrial disorders such as MELAS, Leigh’s syndrome, Rett syndrome, and pediatric MASH.
YTD Price Performance: 9.17%
Average Trading Volume: 23,819
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$28.86M
Learn more about TTI stock on TipRanks’ Stock Analysis page.